• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

    433.76 +0.98 (+0.23%)
    Streaming Delayed Price Updated: 11:13 AM EDT, Mar 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Madrigal Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    2 Under-the-Radar Stocks to Buy and Hold ↗
    These biotechs are slowly making a name for themselves. 
    Via The Motley Fool
    News headline image
    Madrigal (MDGL) Q4 2025 Earnings Call Transcript ↗
    Madrigal (MDGL) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
    Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗
    Via Chartmill
    Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
     
    Via Benzinga
    News headline image
    This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
    GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
    Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
    This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
    Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
    Via The Motley Fool
    News headline image
    Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
    Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
    Via The Motley Fool
    News headline image
    Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗
    The stock has had quite the run following Rezdiffra's 2024 approval by the FDA. 
    Via The Motley Fool
    News headline image
    Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗
    There is a key difference between these two biotechs. 
    Via The Motley Fool
    Topics Bankruptcy
    News headline image
    2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗
    The pharmaceutical leader looks poised to stop the bleeding. 
    Via The Motley Fool
    News headline image
    2 Predictions for Novo Nordisk in 2026 ↗
    The company's worst days might be behind it. 
    Via The Motley Fool
    News headline image
    2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
    They haven't peaked yet. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
    Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗
    Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures. 
    Via Stocktwits
    News headline image
    Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗
     
    Via Benzinga
    News headline image
    Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗
    Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps. 
    Via Benzinga
    News headline image
    Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge ↗
    Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake. 
    Via Chartmill
    News headline image
    A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast ↗
     
    Via Benzinga
    News headline image
    Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock ↗
     
    Via Benzinga
    News headline image
    6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗
    Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. 
    Via Benzinga
    News headline image
    A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts ↗
    In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives. 
    Via Benzinga
    News headline image
    MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template ↗
    Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating. 
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.